Asset Details
Do you wish to reserve the book?
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas
Do you wish to request the book?
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas
2020
Overview
Background
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, with a median survival of approximately 15 months. Semaphorin 3A (Sema3A), known for its axon guidance and antiangiogenic properties, has been implicated in GBM growth. We hypothesized that Sema3A directly inhibits brain tumor stem cell (BTSC) proliferation and drives invasion via Neuropilin 1 (Nrp1) and Plexin A1 (PlxnA1) receptors.
Methods
GBM BTSC cell lines were assayed by immunostaining and PCR for levels of Semaphorin 3A (Sema3A) and its receptors Nrp1 and PlxnA1. Quantitative BrdU, cell cycle and propidium iodide labeling assays were performed following exogenous Sema3A treatment. Quantitative functional 2-D and 3-D invasion assays along with shRNA lentiviral knockdown of Nrp1 and PlxnA1 are also shown. In vivo flank studies comparing tumor growth of knockdown versus control BTSCs were performed. Statistics were performed using GraphPad Prism v7.
Results
Immunostaining and PCR analysis revealed that BTSCs highly express Sema3A and its receptors Nrp1 and PlxnA1, with expression of Nrp1 in the CD133 positive BTSCs, and absence in differentiated tumor cells. Treatment with exogenous Sema3A in quantitative BrdU, cell cycle, and propidium iodide labeling assays demonstrated that Sema3A significantly inhibited BTSC proliferation without inducing cell death. Quantitative functional 2-D and 3-D invasion assays showed that treatment with Sema3A resulted in increased invasion. Using shRNA lentiviruses, knockdown of either NRP1 or PlxnA1 receptors abrogated Sema3A antiproliferative and pro-invasive effects. Interestingly, loss of the receptors mimicked Sema3A effects, inhibiting BTSC proliferation and driving invasion. Furthermore, in vivo studies comparing tumor growth of knockdown and control infected BTSCs implanted into the flanks of nude mice confirmed the decrease in proliferation with receptor KD.
Conclusions
These findings demonstrate the importance of Sema3A signaling in GBM BTSC proliferation and invasion, and its potential as a therapeutic target.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Biomedical and Life Sciences
/ Brain Neoplasms - metabolism
/ Glioma
/ Gliomas
/ Health Promotion and Disease Prevention
/ Humans
/ Ligands
/ Mice
/ Neoplasm Proteins - genetics
/ Neoplasm Proteins - physiology
/ Neoplastic Stem Cells - cytology
/ Neoplastic Stem Cells - metabolism
/ Nerve Tissue Proteins - biosynthesis
/ Nerve Tissue Proteins - genetics
/ Nerve Tissue Proteins - physiology
/ Oncology
/ Plexin
/ Receptors, Cell Surface - biosynthesis
/ Receptors, Cell Surface - genetics
/ Receptors, Cell Surface - physiology
/ RNA, Small Interfering - genetics
/ RNA, Small Interfering - pharmacology
/ Software
/ Specific Pathogen-Free Organisms
/ Tumors
